Skip to content
TrialScanner

NCT02925650

Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease

Phase 1/Phase 2CompletedANVSLead

Registry record

Lead sponsor
Annovis Bio Inc.
Conditions
Alzheimer's Disease
Primary completion
Dec 10, 2021Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02925650 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.